-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $189

Benzinga·04/09/2025 12:02:26
Listen to the news
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $178 to $189.